Newbury Pharmaceuticals Q2: Initial Take - Redeye

Redeye leaves an initial comment following the Q2 report published by Newbury this morning. Although net sales were slightly lower than our estimates, we anticipated relatively conservative figures for the period due to the company's ongoing efforts to establish its commercial presence. With more product launches expected in H2, we believe that sales growth will follow. Overall, the Q2 report was largely in line with our expectations and will likely only cause minor adjustments to our long-term forecasts.

Länk till analysen i sin helhet: https://www.redeye.se/research/892955/newbury-pharmaceuticals-q2-initial-take?utm_source=finwire&utm_medium=RSS